Immunogenicity and safety of the CoronaVac vaccine in patients with cancer receiving active systemic therapy.
Clicks: 81
ID: 276316
2021
To evaluate the immunogenicity and safety of the CoronaVac vaccine in patients with cancer receiving active systemic therapy. This multicenter, prospective, observational study was conducted with 47 patients receiving active systemic therapy for cancer. CoronaVac was administered as two doses (3 μg/day) on days 0 and 28. Antibody level higher than 1 IU/ml was defined as 'immunogenicity.' The immunogenicity rate was 63.8% (30/47) in the entire patient group, 59.5% (25/42) in those receiving at least one cytotoxic drug and 100% (five of five) in those receiving monoclonal antibody or immunotherapy alone. Age was an independent predictive factor for immunogenicity (odds ratio: 0.830; p = 0.043). More than half of cancer patients receiving active systemic therapy developed immunogenicity.
| Reference Key |
karacin2021immunogenicityfuture
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Karacin, Cengiz;Eren, Tulay;Zeynelgil, Esra;Imamoglu, Goksen Inanc;Altinbas, Mustafa;Karadag, Ibrahim;Basal, Fatma Bugdayci;Bilgetekin, Irem;Sutcuoglu, Osman;Yazici, Ozan;Ozdemir, Nuriye;Ozet, Ahmet;Yildiz, Yesim;Esen, Selin Akturk;Ucar, Gokhan;Uncu, Dogan;Dinc, Bedia;Aykan, Musa Baris;Erturk, İsmail;Karadurmus, Nuri;Civelek, Burak;Çelik, İsmail;Ergun, Yakup;Dogan, Mutlu;Oksuzoglu, Omur Berna; |
| Journal | Future oncology (London, England) |
| Year | 2021 |
| DOI | 10.2217/fon-2021-0597 |
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.